This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008:1:83-91.

doi: 10.4137/cpath.s667. Epub 2008 Jul 28.

Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy

Li Lin¹

Affiliations

PMID: 21876656
PMCID: PMC3160008
DOI: 10.4137/cpath.s667

Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy

Li Lin. Clin Med Pathol. 2008.

. 2008:1:83-91.

doi: 10.4137/cpath.s667. Epub 2008 Jul 28.

Author

Li Lin¹

Affiliation

¹ Key laboratory of cellular physiology, Shanxi Medical University, China.

PMID: 21876656
PMCID: PMC3160008
DOI: 10.4137/cpath.s667

No abstract available

Keywords: Alzheimer’s disease; diabetes; glucagon-like peptide 1.

PubMed Disclaimer

Figures

Figure 1. — Figure 1.
Common pathological processes in AD and T2DM. Ninety percent homologous structure was shown between Aβ which is a hallmark pathology in AD and IAPP which is involved in T2DM. Insulin abnormality is attributed to AD by promoting Aβ deposite, and τ protein hyperphosphorylation. GSK3 is a key kinase to promoteτ protein hyperphosphorylation and glycogen biosynthesis. Abbreviations: AD: Alzheimer’s disease; T2DM: Type 2 diabetes mellitus; IAPP: islet amyloid polypeptide; Aβ: Amyloid β; GSK3: glycogen synthase kinase.

See this image and copyright information in PMC

Similar articles

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
Camins A, Ettcheto M, Busquets O, Manzine PR, Castro-Torres RD, Beas-Zarate C, Verdaguer E, Sureda FX, Bulló M, Olloquequi J, Auladell C, Folch J. Camins A, et al. Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1. Expert Opin Investig Drugs. 2019. PMID: 30480461 No abstract available.
[Alzheimer's disease and diabetes - the common pathogenesis].
Halmos T, Suba I. Halmos T, et al. Neuropsychopharmacol Hung. 2016 Mar;18(1):5-19. Neuropsychopharmacol Hung. 2016. PMID: 27038867 Hungarian.
[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
Wang XH, Yang W, Qi JS. Wang XH, et al. Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406. Sheng Li Xue Bao. 2010. PMID: 20945041 Review. Chinese.
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
McClean PL, Gault VA, Harriott P, Hölscher C. McClean PL, et al. Eur J Pharmacol. 2010 Mar 25;630(1-3):158-62. doi: 10.1016/j.ejphar.2009.12.023. Epub 2009 Dec 24. Eur J Pharmacol. 2010. PMID: 20035739
New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.
Hölscher C. Hölscher C. Neural Regen Res. 2014 Nov 1;9(21):1870-3. doi: 10.4103/1673-5374.145342. Neural Regen Res. 2014. PMID: 25558231 Free PMC article. Review.

See all similar articles

Cited by

Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.
Rizvi SM, Shaikh S, Naaz D, Shakil S, Ahmad A, Haneef M, Abuzenadah AM. Rizvi SM, et al. Neurochem Res. 2016 Jun;41(6):1475-82. doi: 10.1007/s11064-016-1859-3. Epub 2016 Feb 17. Neurochem Res. 2016. PMID: 26886763
Therapeutic Potential of Genipin in Central Neurodegenerative Diseases.
Li Y, Li L, Hölscher C. Li Y, et al. CNS Drugs. 2016 Oct;30(10):889-97. doi: 10.1007/s40263-016-0369-9. CNS Drugs. 2016. PMID: 27395402 Review.
Association of impaired fasting glucose and Type 2 Diabetes Mellitus with brain volume changes in Alzheimer's Disease patients analyzed by MRI: a retrospective study.
Wang W, Wong L, Shi L, Luo Y, Liang Z, Dong C, Song Q, Liu T, Zhang Q, Liu A, Miao Y, Wu J. Wang W, et al. PeerJ. 2020 Aug 27;8:e9801. doi: 10.7717/peerj.9801. eCollection 2020. PeerJ. 2020. PMID: 32913679 Free PMC article.
Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.
Hnilicova P, Kantorova E, Sutovsky S, Grofik M, Zelenak K, Kurca E, Zilka N, Parvanovova P, Kolisek M. Hnilicova P, et al. Int J Mol Sci. 2023 Feb 7;24(4):3325. doi: 10.3390/ijms24043325. Int J Mol Sci. 2023. PMID: 36834741 Free PMC article. Review.
Geniposide prevents rotenone-induced apoptosis in primary cultured neurons.
Li L, Zhao J, Liu K, Li GL, Han YQ, Liu YZ. Li L, et al. Neural Regen Res. 2015 Oct;10(10):1617-21. doi: 10.4103/1673-5374.167760. Neural Regen Res. 2015. PMID: 26692859 Free PMC article.

See all "Cited by" articles

References

1. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev. 2007;56:384–402. - PubMed
1. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nature Clinical Practice Neurology. 2006;2:159–66. - PubMed
1. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004;63:1181–6. - PubMed
1. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyper-insulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187–92. - PubMed
1. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937–42. - PubMed

LinkOut - more resources

Full Text Sources